GlassScriptPhysician profile
Derek A Mccoy
NPI 1285827261
$3,472.33
in general payments reported to CMS, 2019-2025
27 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 91% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $575 · 2024: $1,324 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.72 |
| Education | $159.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $607.59 | 2023-2025 | Farxiga, Fasenra, Airsupra |
| Novo Nordisk INC | $595.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $439.34 | 2023-2025 | |
| Astellas Pharma US INC | $343.17 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $323.78 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $198.49 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Exact Sciences Corporation | $92.24 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $80.70 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $80.62 | 2024-2025 | Rexulti |
| Abbvie INC. | $79.25 | 2025 | |
| Dexcom, INC. | $66.31 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $65.61 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $57.67 | 2023-2025 | Nexletol |
| Vivaquant INC, Dba Rhythm Express | $57.40 | 2024 | Rhythm Express |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.32 | 2023-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $48.65 | 2025 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $42.77 | 2024 | Trintellix |
| Sumitomo Pharma America, INC. | $40.24 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $34.74 | 2023-2024 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $32.40 | 2023-2024 | Camzyos |
| Abbott Laboratories | $28.49 | 2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $23.80 | 2024 | Strensiq |
| Medicomp INC | $18.59 | 2024 | Telepatch Cardiac Monitor |
| Insulet Corporation | $18.46 | 2023 | Omnipod |
| Resmed Corp | $17.09 | 2025 | |
| Seqirus USA INC | $16.56 | 2024 | Flucelvax, Fluad |
| Medtronic, INC. | $13.11 | 2023 | Closurefast |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.